Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Clinical trial NCT06908772 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06908772
Sponsor: Shanghai JMT-Bio Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression

Start date: 2025-04-01
Primary completion: 2028-12-31
Enrollment: 390

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.